Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
News about Daré Bioscience, Inc. (NASDAQ: DARE) centers on its efforts to advance and commercialize women’s health products across contraception, sexual health, vaginal health and menopause. Company press releases highlight progress on clinical programs, grant-funded research, regulatory interactions and commercialization plans for both prescription and consumer health offerings.
Recent news has focused on DARE to PLAY Sildenafil Cream, a proprietary topical arousal cream designed specifically for women. Daré reports that this first-of-its-kind topical sildenafil formulation for women has been evaluated in multiple clinical studies and is being introduced via a Section 503B outsourcing facility as an evidence-backed option to enhance genital blood flow and arousal response. Updates describe pre-order availability in select U.S. states, webinar events with sexual health clinicians and the role of DARE to PLAY in the company’s broader 503B compounding strategy.
Another major news theme is Ovaprene, Daré’s investigational hormone-free monthly intravaginal contraceptive. Releases discuss interim Phase 3 results, data safety monitoring board recommendations to continue the pivotal study without modification, and the return of commercialization rights to Daré from a prior license partner. These items provide context on clinical progress, safety and tolerability findings, and the company’s plans to maximize the asset’s value.
Daré’s news flow also covers non-dilutive grant funding and collaborations, including multi-year support for DARE-LARC1, a long-acting contraceptive based on the DARE-IDDS programmable drug delivery platform, and grants for non-hormonal intravaginal contraceptive research and HPV-related programs. Corporate updates detail quarterly financial results, Nasdaq listing matters, and strategic initiatives that combine near-term revenue opportunities with long-term pipeline development. Investors and observers can use the DARE news page to follow these developments and track how clinical, commercial and funding milestones evolve over time.
Daré Bioscience (NASDAQ: DARE) reported full-year 2025 results and a business update on March 26, 2026. Key facts: $24.7M cash, $3.4M working capital, $20.8M net equity proceeds, and significant non-dilutive funding including $13.6M from Gates and $4.5M ARPA-H.
Commercial launches planned: DARE to PLAY dispensing and Flora Sync LF5 consumer sales expected Q2 2026; DARE to RECLAIM targeted in 2027. Ovaprene Phase 3 enrollment expected to complete in 2026; DARE-HPV advancing to Phase 2 with ARPA-H support.
Daré Bioscience (NASDAQ: DARE) announced DARE to PLAY™ Sildenafil Cream, a prescription topical sildenafil product developed and clinically studied specifically for women, and available as a Section 503B compounded product. Clinical studies showed increased genital blood flow within 10–15 minutes and improved arousal sensations using clinically validated endpoints. Daré highlights the product as non‑hormonal, fast‑acting, and ready for prescribers. The company is concurrently conducting a Regulation A offering open to all investors to support its women’s health pipeline.
Daré Bioscience (NASDAQ: DARE) will host a conference call and live webcast at 4:30 p.m. ET on March 26, 2026 to review full year 2025 financial results and provide a company update.
Dial-in numbers are (646) 307-1963 or (800) 715-9871 with conference ID 1717423. The webcast is at http://ir.darebioscience.com and will be archived for replay until April 9, 2026.
Daré Bioscience (NASDAQ: DARE) received a revised NIH Notice of Award, obligating approximately $2.0 million total for DARE-PTB1, an investigational intravaginal ring (IVR) to prevent preterm birth. The notice, dated March 11, 2026, extends the second tranche (about $1.0 million) through November 30, 2026.
DARE-PTB1 is designed to deliver bio-identical progesterone continuously for up to a 14-day period and leverages learnings from prior DARE IVR hormone trials. The award reflects Daré's use of non-dilutive funding to advance its women's health pipeline.
Daré Bioscience (NASDAQ: DARE) announced CEO Sabrina Martucci Johnson’s participation in a Virtual Investor segment highlighting the FDA clearance of the IND for DARE-HPV on March 12, 2026 and plans to advance the program into a Phase 2 clinical study.
The CEO outlined how DARE-HPV would differ from current management of persistent high-risk HPV, noted the absence of any FDA-approved drug therapy for that condition, described anticipated timelines, potential risks, upcoming catalysts, and cited non-dilutive ARPA-H funding supporting the program.
Daré Bioscience (NASDAQ: DARE) announced FDA clearance of its IND for DARE-HPV, enabling initiation of a planned Phase 2 study for a topical lopinavir/ritonavir vaginal insert to treat persistent high‑risk HPV infection. The program is supported by a $10 million ARPA-H contract, with $6.5 million received to date. The study aims to evaluate safety and antiviral activity and the company is preparing to start the trial in 2026.
DARE-HPV targets an unmet need: there are currently no FDA‑approved pharmacologic treatments for high‑risk HPV, the primary cause of cervical cancer.
Dare Bioscience (NASDAQ: DARE) launched nationwide telehealth consultations for DARE to PLAY™ Sildenafil Cream, a clinically studied topical arousal cream for women shown to increase genital blood flow in 10–15 minutes and improve arousal on validated endpoints. Pre-fulfillment prescribing is available in all 50 states with prescriptions held until pharmacy dispensing begins via a 503B outsourcing facility. Early access benefits include a complimentary telehealth visit during pre-fulfillment, 25% off initial order and refills, and priority fulfillment once dispensing starts.
Dare Bioscience (NASDAQ: DARE) announced pre-orders by prescription for DARE to PLAY™ Sildenafil Cream beginning Dec 10, 2025, with commercial rollout through a 503B outsourcing facility.
The topical sildenafil cream is described as the first evidence-backed formulation for women, supported by toxicology studies, multiple clinical trials including a randomized placebo-controlled study of 200 women, and peer-reviewed publications. Prescriptions can be filled in CT, FL, IN, MO, NH, NJ, OR, PA, RI, and UT and will ship within 45 days during the pre-order phase. The product is a compounded 503B drug and is not FDA approved.
Daré Bioscience (NASDAQ: DARE) announced Bayer will return all rights to Ovaprene after Bayer elected to terminate the license; termination is effective February 2026. Daré will hold consolidated global commercialization rights for the late-stage, first-in-category, hormone-free monthly intravaginal contraceptive while its pivotal Phase 3 trial continues.
Key facts: positive interim Phase 3 data reported in July 2025 showing consistent safety and tolerability and pregnancy rates aligned with pre-pivotal results; enrollment is expected to complete in 2026; the trial continues with non-dilutive grant funding, including a Gates Foundation award announced in 2024. Daré plans to evaluate partnership and commercialization options and pursue a PMA strategy with the FDA CDRH.
Daré Bioscience (NASDAQ: DARE) received an additional ~$3.6 million payment under an existing Gates Foundation grant on Nov 24, 2025. The tranche is part of an up-to-approximately $10.7 million grant originally announced in November 2024 and follows an initial ~$5.4 million payment in 2024. Funds will support preclinical work to identify and develop a non-hormonal intravaginal contraceptive for low- and middle-income country settings and activities on product design, formulation, acceptability, and early-stage development. In parallel, initial grant funding continues to support enrollment in the pivotal Phase 3 trial of Ovaprene (ClinicalTrials.gov ID: NCT06127199). Future payments depend on achievement of specified milestones.